Matt Cohen

Managing Partner, Osage University Partners, Life Science VC @OUP_VC. PhD, recovering management consultant

[Matt Cohen @mcohenOUP]

@LifeSciVC Been a fun afternoon! We Are!

[Matt Cohen @mcohenOUP]

@oakazaki @plainyogurt21 I also wondered about this. You might expect insomnia AEs if that was the case, though. Could it be something as simple as more total pills (drug or placebo) given at the higher dose? Could also just be noise with small n. 🤷

[Matt Cohen @mcohenOUP]

@oakazaki @plainyogurt21 Sleep deprived HVs weren’t tested at the middle dose. It’s in the footnote.

[Matt Cohen @mcohenOUP]

Thrilled to support S2S and all of the incredible academic innovation being showcased. #Science2Startup

[Osage Univ. Partners @OUP_VC]

OUP's @mcohenOUP, Ph.D. will join researchers, entrepreneurs and top investors this May for the 3rd annual #Science2Startup!

Learn more about the event and the how it is supporting the future of #biotech: https://t.co/I2X81wF5Iv

[Matt Cohen @mcohenOUP]

@debpalestrant @5amVentures Thanks, @debpalestrant ! @Mitra_DosM and I fully agree - best first meeting of JPM we could’ve had. Let’s make it a thing!

[ArsenalBio @ArsenalBio]

The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development: https://t.co/kRFz2a6iwX

[David Dorsey @david__dorsey]

I’ve received messages from many friends and colleagues asking how how they can donate to causes in memory of my wife, Renee, and daughters, Parker and June, since the accident last week. I posted a couple of ideas here: https://t.co/pCAtjSbrlT

[Osage Univ. Partners @OUP_VC]

#Science2Startup is a one-day symposium for therapeutics researchers to present startup ideas to leaders in the #biotech space on May 23, 2023 in Boston.

Apply here by December 5: https://t.co/I2X81wExSX

@FPrimeCapital @atlasventure @5amVentures @OUP_VC #RACapital

[Ken Rosenthal @Ken_Rosenthal]

Firing Joe Girardi wouldn’t fix Phillies’ problems. Column: https://t.co/RBuMUmXLEk

[Matt Cohen @mcohenOUP]

@ideapharma @AppleHelix @MenePangalos @LifeSciVC I agree that companies will withhold launch for indication expansion early and that’s not ideal for patients. And value data is good. Market access is one element. Physician comfort is another and that more time/use based than anything. Will be fascinating to watch.

[Matt Cohen @mcohenOUP]

@ideapharma @AppleHelix @MenePangalos @LifeSciVC Thx. Has 13% of drug launches to peak in yr 3 gone up since 2018? Were these Medicare pop launches or rare disease with no other options? The data is interesting. What’s current avg across all launches in last 10 yrs? Would be interesting to see. I’m admittedly out of date

[Matt Cohen @mcohenOUP]

@ideapharma @AppleHelix @MenePangalos @LifeSciVC Peak sales ramp in 3 year would be news to me. The assumptions I used building these forecasts based on data (10 years ago, admittedly), were 7 years on average. Is there any recently published data on this you could point me to?

[Matt Cohen @mcohenOUP]

@ideapharma @AppleHelix @MenePangalos @LifeSciVC Every pharma company plans to launch. I’m not sure what you’re saying, tbh. The ramp avg is 7 years and it’s not due to a launch delay. Adoption is always slow. What do you mean by lifecycling earlier? What would you spend on earlier that helps maximize revenue before yr 9?

[Matt Cohen @mcohenOUP]

@ideapharma @AppleHelix @MenePangalos @LifeSciVC How do you improve launch ramps? They on average take 7 years or so to hit peak sales so the expectation is you are cutting ~50% off the sales potential given half of it comes in years 8-13. Lower R&D costs help NPV but not enough. How do you launch faster more widely?

[Alex Coffey @byalexcoffey]

Dancing on my own

[Matt Cohen @mcohenOUP]

@BDeHaven616 😂

[Canaan @canaanpartners]

Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton @JuliePapanek @jesse_yeji

Read full piece with BI subscription at: https://t.co/8wkPzH1Ywz

[Matt Cohen @mcohenOUP]

@PearlF @ChrisHeery @michael_gilman I believe that was analysis done by @ohadhammer and from my recollection of what it was 10 years ago it’s up a lot. CROs and pass through costs from trial sites certainly aren’t getting cheaper.

[Matt Cohen @mcohenOUP]

@DuaneReadeSanta @MSollender It says RECIST in the methods